TNF-&agr; Receptor 1 Expression Predicts Poor Prognosis of Diffuse Large B-cell Lymphoma, Not Otherwise Specified

We have previously shown that in tumor specimens from patients with diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), the tumor necrosis factor-&agr; (TNF-&agr;)-positive type correlates with a poorer prognosis compared with the TNF-&agr;-negative type. In the present study, we further evaluated 60 lymphoma tissue specimens from patients with DLBCL, NOS by immunohistochemical staining with antibodies against TNF-&agr; receptor 1 (TNFR1) and TNF-&agr; receptor 2 (TNFR2). Our results demonstrated that 31 cases (52%) were positive and 29 (48%) were negative for TNFR1 and that the TNFR1-positive cases were significantly correlated with a poorer overall survival (OS; P=0.0006, log rank test) than the TNFR1-negative cases. The TNFR2-positive cases tended to have a poorer OS than the TNFR2-negative cases, although the difference was not significant. TNFR1 expression in tumor cells was a significant prognostic factor for OS and was independent of the International Prognostic Index (IPI). Among 31 TNF-&agr;-positive DLBCL, NOS cases, 27 (87%) were positive and 4 (13%) were negative for TNFR1. Both TNF-&agr;-positive and TNFR1-positive cases were significantly correlated with a poorer OS compared with the TNF-&agr;-positive but TNFR1-negative cases. Twenty-seven cases (45%) with the TNF-&agr;-positive and TNFR1-positive subtype of DLBCL, NOS had a poorer prognosis for OS and progression-free survival compared with the 33 cases (55%) with the remaining subtypes, and the TNF-&agr;-positive and TNFR1-positive subtype of DLBCL, NOS was also shown to be independent of the IPI. In addition to the IPI, the prognosis of patients can be more accurately identified by evaluating both TNF-&agr; and TNFR1 expression.

[1]  L. Medeiros,et al.  Diffuse Large B-Cell Lymphoma, Not Otherwise Specified , 2013 .

[2]  T. Hanafusa,et al.  TNF-&agr; Expression in Tumor Cells as a Novel Prognostic Marker for Diffuse Large B-cell Lymphoma, Not Otherwise Specified , 2014, The American journal of surgical pathology.

[3]  P. Tak,et al.  Advances in rheumatology: new targeted therapeutics , 2011, Arthritis research & therapy.

[4]  Y. Wu,et al.  TNF-α/NF-κB/Snail pathway in cancer cell migration and invasion , 2010, British Journal of Cancer.

[5]  F. Balkwill.  Tumour necrosis factor and cancer , 2009, Nature Reviews Cancer.

[6]  J. Bradley,et al.  TNF‐mediated inflammatory disease , 2008, The Journal of pathology.

[7]  C. Lovly,et al.  The role of NF-κB-1 and NF-κB-2-mediated resistance to apoptosis in lymphomas , 2006 .

[8]  C. Lovly,et al.  The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Michael Karin,et al.  NF-kappaB: linking inflammation and immunity to cancer development and progression. , 2005, Nature reviews. Immunology.

[10]  B. Aggarwal,et al.  Nuclear factor-kappaB activation mediates cellular transformation, proliferation, invasion angiogenesis and metastasis of cancer. , 2004, Cancer treatment and research.

[11]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[12]  B. Aggarwal.  Signalling pathways of the TNF superfamily: a double-edged sword , 2003, Nature Reviews Immunology.

[13]  Takashi Akasaka,et al.  De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. , 2002, Blood.

[14]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[15]  N. Colburn,et al.  Transformation nonresponsive cells owe their resistance to lack of p65/nuclear factor-kappaB activation. , 2001, Cancer research.

[16]  R. Fisher.  Diffuse large-cell lymphoma. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  K. Naresh,et al.  Circulating levels of TNF alpha and TNF receptor superfamily members in lymphoid neoplasia. , 2000, American journal of hematology.

[18]  A. Cope,et al.  Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion. Relevance to the pathophysiology of septic shock. , 1998, The Journal of clinical investigation.

[19]  B. Nathwani,et al.  A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .

[20]  B. Coiffier,et al.  ELEVATED CIRCULATING LEVELS OF TNFα AND ITS p55 SOLUBLE RECEPTOR ARE ASSOCIATED WITH AN ADVERSE PROGNOSIS IN LYMPHOMA PATIENTS , 1996, British journal of haematology.

[21]  J. Strominger,et al.  Tumor necrosis factor alpha is an autocrine growth factor for normal human B cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Shipp.  Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease? , 1994, Blood.

[23]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[24]  D. Wallach,et al.  Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. , 1991, Cancer research.

[25]  D. Wallach,et al.  A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. , 1989, The Journal of biological chemistry.

[26]  H. Heimpel,et al.  Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia. , 1989, Blood.

[27]  M. Turner,et al.  TUMOUR NECROSIS FACTOR AS AN AUTOCRINE TUMOUR GROWTH FACTOR FOR CHRONIC B-CELL MALIGNANCIES , 1988, The Lancet.

[28]  P. Black,et al.  Shedding from the cell surface of normal and cancer cells. , 1980, Advances in cancer research.

[29]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.